Targeting Hsp90/Hsp70-based protein quality control for treatment of adult onset neurodegenerative diseases

Annual Review of Pharmacology and Toxicology

Volumn 55, Issue , 2015, Pages 353-371

  Pratt, William B ^a   Gestwicki, Jason E ^b   Osawa, Yoichi ^a   Lieberman, Andrew P ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CHIP; Neurodegeneration; Proteasome; Protein aggregation; Ubiquitination

Indexed keywords

1 ETHYL 2 [[3 ETHYL 5 (3 METHYLBENZOTHIAZOLIN 2 YLIDENE) 4 OXOTHIAZOLIDIN 2 YLIDENE]METHYL]PYRIDINIUM CHLORIDE; ALPHA SYNUCLEIN; ANSAMYCIN DERIVATIVE; CHAPERONE; GELDANAMYCIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HERBIMYCIN A; POLYGLUTAMINE; UNCLASSIFIED DRUG; YM 1; NEUROPROTECTIVE AGENT; PROTEASOME; STUB1 PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DISEASE COURSE; HUMAN; HUNTINGTON CHOREA; KENNEDY DISEASE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FUNCTION; PROTEIN HOMEOSTASIS; PROTEIN QUALITY; PROTEIN STABILITY; REVIEW; TURNOVER TIME; UBIQUITINATION; ADULT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; METABOLISM; NERVOUS SYSTEM; NEURODEGENERATIVE DISEASES; ONSET AGE; PATHOPHYSIOLOGY; PROTEIN DENATURATION; PROTEIN FOLDING; SIGNAL TRANSDUCTION;

ANIMALIA;

ADULT; AGE OF ONSET; ANIMALS; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; NERVOUS SYSTEM; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN DENATURATION; PROTEIN FOLDING; PROTEIN STABILITY; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84910031803     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010814-124332     Document Type: Review

References (134)

1. Pratt WB, Toft DO. 2003. Regulation of signaling protein function and trafficking by the hsp90/hsp70- based chaperone machinery. Exp. Biol. Med. (Maywood) 228:111-33
2. Sherman MY, Goldberg AL. 2001. Cellular defenses against unfolded proteins: A cell biologist thinks about neurodegenerative diseases. Neuron 29:15-32
3. Isaacs JS, Xu W, Neckers L. 2003. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3:213-17
4. Pratt WB, Morishima Y, Peng HM, Osawa Y. 2010. Proposal for a role of the Hsp90/Hsp70-based chaperone machinery in making triage decisions when proteins undergo oxidative and toxic damage. Exp. Biol. Med. (Maywood) 235:278-89
5. Pratt WB, Morishima Y, Osawa Y. 2008. The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J. Biol. Chem. 283:22885-89
6. Peng HM, Morishima Y, Pratt WB, Osawa Y. 2012. Modulation of heme/substrate binding cleft of neuronal nitric-oxide synthase (nNOS) regulates binding of Hsp90 and Hsp70 proteins and nNOS ubiquitination. J. Biol. Chem. 287:1556-65
7. Hershko A, Ciechanover A. 1998. The ubiquitin system. Annu. Rev. Biochem. 67:425-79
8. Cyr DM, H ohfeld J, Patterson C. 2002. Protein quality control: U-box-containing E3 ubiquitin ligases join the fold. Trends Biochem. Sci. 27:368-75
9. Connell P, Ballinger CA, Jiang J, Wu Y, Thomson LJ, et al. 2001. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat. Cell Biol. 3:93-96
10. Zhou P, Fernandes N, Dodge IL, Redd AL, Rao N, et al. 2003. ErbB2 degradation mediated by the co-chaperone protein CHIP. J. Biol. Chem. 278:13829-37
11. Jana NR, Dikshit P, Goswami A, Kotliarova S, Murata S, et al. 2005. Co-chaperone CHIP associates with expanded polyglutamine protein and promotes their degradation by proteasomes. J. Biol. Chem. 280:11635-40
12. Morishima Y, Wang AM, Yu Z, Pratt WB, Osawa Y, Lieberman AP. 2008. CHIP deletion reveals functional redundancy of E3 ligases in promoting degradation of both signaling proteins and expanded glutamine proteins. Hum. Mol. Genet. 17:3942-52
13. Tateishi Y, Kawabe Y, Chiba T, Murata S, Ishikawa K, et al. 2004. Ligand-dependent switching of ubiquitin-proteasome pathways for estrogen receptor. EMBO J. 23:4813-23
14. H ohfeld J, Cyr DM, Patterson C. 2001. From the cradle to the grave: molecular chaperones that may choose between folding and degradation. EMBO Rep. 2:885-90
15. Peng HM, Morishima Y, Clapp KM, Lau M, Pratt WB, Osawa Y. 2009. Dynamic cycling with Hsp90 stabilizes neuronal nitric oxide synthase through calmodulin-dependent inhibition of ubiquitination. Biochemistry 48:8483-90
16. Pratt WB, Toft DO. 1997. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr. Rev. 18:306-60
17. Stancato LF, Chow YH, Hutchinson KA, Perdew GH, Jove R, Pratt WB. 1993. Raf exists in a native heterocomplex with hsp90 and p50 that can be reconstituted in a cell-free system. J. Biol. Chem. 268:21711-16
18. Xu W, Mimnaugh E, Rosser MF, Nicchitta C, Marcu M, et al. 2001. Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90. J. Biol. Chem. 276:3702-8
19. Citri A, Alroy I, Lavi S, Rubin C, Xu W, et al. 2002. Drug-induced ubiquitylation and degradation of ErbB2 receptor tyrosine kinases: implications for cancer therapy. EMBO J. 21:2407-17
20. Wijayaratne AL, McDonnell DP. 2001. The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 276:35684-92
21. Peng HM, Morishima Y, Jenkins GJ, Dunbar AY, Lau M, et al. 2004. Ubiquitylation of neuronal nitricoxide synthase by CHIP, a chaperone-dependent E3 ligase. J. Biol. Chem. 279:52970-77
22. Fan M, Park A, Nephew KP. 2005. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-α. Mol. Endocrinol. 19:2901-14
23. Whitesell L, Lindquist SL. 2005. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 5:761-72
24. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. 1994. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 91:8324-28
25. Sepp-Lorenzino L, Ma Z, Lebwohl DE, Vinitsky A, Rosen N. 1995. Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases. J. Biol. Chem. 270:16580-87
26. Mimnaugh EG, Chavany C, Neckers L. 1996. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271:22796-801
27. Dutta R, Inouye M. 2000. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem. Sci. 25:24-28
28. Roe SM, Prodromou C, OBrien R, Ladbury JE, Piper PW, Pearl LH. 1999. Structural basis for inhibition of theHsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 42:260-66
29. Neckers L, Workman P. 2012. Hsp90 molecular chaperone inhibitors: are we there yet? Clin. Cancer Res. 18:64-76
30. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ. 2004. Hsp70 reduces α-synuclein aggregation and toxicity. J. Biol. Chem. 279:25497-502
31. Jana NR, Tanaka M, Wang G, Nukina N. 2000. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet. 9:2009-18
32. Bailey CK, Andriola IF, Kampinga HH, Merry DE. 2002. Molecular chaperones enhance the degradation of expanded polyglutamine repeat androgen receptor in a cellular model of spinal and bulbar muscular atrophy. Hum. Mol. Genet. 11:515-23
33. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R. 1998. Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94:471-80
34. Muchowski PJ, Wacker JL. 2005. Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci. 6:11-22
35. Auluck PK, Bonini NM. 2002. Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 8:1185-86
36. Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, et al. 2004. Progressive decrease in chaperone protein levels in a mouse model of Huntingtons disease and induction of stress proteins as a therapeutic approach. Hum. Mol. Genet. 13:1389-405
37. Sittler A, Lurz R, Lueder G, Priller J, Hayer-Hartl MK, et al. 2001. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntingtons disease. Hum. Mol. Genet. 10:1307-15
38. Thomas M, Harrell JM, Morishima Y, Peng HM, Pratt WB, Lieberman AP. 2006. Pharmacologic and genetic inhibition of hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor without stress protein induction. Hum. Mol. Genet. 15:1876-83
39. McLean PJ, Klucken J, Shin Y, Hyman BT. 2004. Geldanamycin induces Hsp70 and prevents α-synuclein aggregation and toxicity in vitro. Biochem. Biophys. Res. Commun. 321:665-69
40. Zietkiewicz S, Lewandowska A, Stocki P, Liberek K. 2006. Hsp70 chaperone machine remodels protein aggregates at the initial step of Hsp70-Hsp100-dependent disaggregation. J. Biol. Chem. 281:7022-29
41. Powers MV, Jones K, Barillari C, Westwood I, vanMonfort RLM, Workman P. 2010. Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 9:1542-50
42. Wang AM, Morishima Y, Clapp KM, Peng HM, Pratt WB, et al. 2010. Inhibition of hsp70 by methylene blue affects signaling protein function and ubiquitination and modulates polyglutamine protein degradation. J. Biol. Chem. 285:15714-23
43. Howarth JL, Glover CPJ, Uney JB. 2009. HSP70 interacting protein prevents the accumulation of inclusions in polyglutamine disease. J. Neurochem. 108:945-51
44. Mayer MP, Brehmer D, Gassler CS, Bukau B. 2001. Hsp70 chaperone machines. Adv. Protein Chem. 59:1-44
45. Wang AM, Miyata Y, Klinedinst S, Peng HM, Chua JP, et al. 2013. Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation. Nat. Chem. Biol. 9:112-18
46. Roodveldt C, Bertoncini CW, Andersson A, van derGoot AT, Hsu ST, et al. 2009. Chaperone proteostasis in Parkinsons disease: stabilization of the Hsp70/α-Synuclein complex by Hip. EMBO J. 28:3758-70
47. Rousaki A, Miyata Y, Jinwal UK, Dicky CA, Gestwicki JE, Zuiderweg ER. 2011. Allosteric drugs: the interaction of antitumor compoundMKT-077 with human Hsp70 chaperones. J. Mol. Biol. 411:614-32
48. Morishima Y, Lau M, Peng HM, Miyata Y, Gestwicki JE, et al. 2011. Heme-dependent activation of neuronal nitric oxide synthase by cytosol is due to an Hsp70-dependent, thioredoxin-mediated thioldisulfide interchange in the heme/substrate binding cleft. Biochemistry 50:7146-56
49. Zoghbi HY, Orr HT. 2000. Glutamine repeats and neurodegeneration. Annu. Rev. Neurosci. 23:217-47
50. Orr HT, Zoghbi HY. 2007. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30:575-621
51. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. 1991. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-79
52. Merry DE, Kobayashi Y, Bailey CK, Taye AA, Fischbeck KH. 1998. Cleavage, aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular atrophy. Hum. Mol. Genet. 7:693-701
53. Li M, Chevalier-Larsen ES, Merry DE, Diamond MI. 2007. Soluble androgen receptor oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J. Biol. Chem. 282:3157-64
54. Adachi H, Katsuno M, Minamiyama M, Waza M, Sang C, et al. 2005. Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA patients. Brain 128:659-70
55. Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, et al. 2003. Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. Hum. Mol. Genet. 12:749-57
56. Kopito RR. 2000. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10:524-30
57. Waza M, Adachi H, Katsuno M, Minamiyama M, Sang C, et al. 2005. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat. Med. 11:1088-95
58. Pratt WB, Galigniana MD, Harrell JM, DeFranco DB. 2004. Role of hsp90 and the hsp90-binding immunophilins in signaling protein movement. Cell Signal. 16:857-72
59. Tokui K, Adachi H, Waza JM, Katsuno M, Minamiyama M, et al. 2009. 17-DMAG ameliorates polyglutamine-mediated motor neuron degeneration through well-preserved proteasome function in an SBMA model mouse. Hum. Mol. Genet. 18:898-910
60. Stenoien DL, Cummings CJ, Adams HP, Mancini MG, Patel K, et al. 1999. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet. 8:731-41
61. Abel A, Walcott J, Woods J, Duda J, Merry DE. 2001. Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum. Mol. Genet. 10:107-16
62. Kobayashi Y, Kume A, Li M, Doyu M, Hata M, et al. 2000. Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J. Biol. Chem. 275:8772-78
63. Adachi H, Katsuno M, Minamiyama M, Sang C, Pagoulatos G, et al. 2003. Heat shock protein 70 chaperone overexpression ameliorates phenotypes of the spinal and bulbar muscular atrophy transgenic mouse model by reducing nuclear-localized mutant androgen receptor protein. J. Neurosci. 23:2203-11
64. Adachi H, Waza M, Takui K, Katsuno M, Minamiyama M, et al. 2007. CHIP overexpression reduces mutant androgen receptor protein and ameliorates phenotypes of the spinal and bulbarmuscular atrophy transgenic mouse model. J. Neurosci. 27:5115-26
65. Imarisio S, Carmichael J, Korolchuk V, Chen CW, Saiki S, et al. 2008. Huntingtons disease: from pathology and genetics to potential therapies. Biochem. J. 412:191-209
66. Truant R, Atwal RS, Burtnik A. 2007. Nucleocytoplasmic trafficking and transcription effects of huntingtin in Huntingtons disease. Prog. Neurobiol. 83:211-27
67. Gunawardena S, Her LS, Brusch RG, Layman RA, Niesman IR, et al. 2003. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40:25-40
68. Gauthier LR, Charrin BC, Borrell-Pages M, Dumpierre JP, Rangone H, et al. 2004. Huntington controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127-38
69. Caviston JP, Ross JL, Antony SM, Tokito M, Holzbaur ELF. 2007. Huntingtin facilitates dynein/dynactin-mediated vesicle transport. Proc. Natl. Acad. Sci. USA 104:10045-50
70. Caviston JP, Holzbaur ELF. 2009. Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 19:147-55
71. Lee WC, Yoshihara M, Littleton JJ. 2004. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model ofHuntingtons disease. Proc. Natl. Acad. Sci. USA 101:3224-29
72. Saudou F, Finkbeiner S, Devys D, Greenberg ME. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66
73. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. 2004. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805-10
74. Mukai H, Iregawa T, Goyama E, Tanaka S, Bence NF, et al. 2005. Formation ofmorphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells. Proc. Natl. Acad. Sci. USA 102:10887-92
75. Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. 2003. Time course of early motor and neuropathological anomalies in a knock-in mousemodel ofHuntingtons disease with 140 CAG repeats. J. Comp. Neurol. 465:11-26
76. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, et al. 1997. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-48
77. Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, et al. 1999. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. Hum. Mol. Genet. 8:397-407
78. Baldo B, Weiss A, Parker CN, Bibel M, Paganetti P, Kaupmann K. 2012. A screen for enhancers of clearance identifies huntingtin as a heat shock protein 90 (Hsp90) client protein. J. Biol. Chem. 287:1406-14
79. Herbst M, Wanker EE. 2007. Small molecule inducers of heat shock response reduce polyQ-mediated huntingtin aggregation. Neurodegener. Dis. 4:254-60
80. Fujikake N, Nagai Y, Popiel HA, Okamoto Y, Yamaguchi M, Toda T. 2008. Heat shock transcription factor 1-activating compounds suppress polyglutamine-induced neurodegeneration through induction of multiple molecular chaperones. J. Biol. Chem. 283:26188-97
81. Labbadia J, Cunliffe H, Weiss A, Katsyuba E, Sathasivam K, et al. 2011. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. J. Clin. Invest. 121:3306-19
82. Krobitsch S, Lindquist S. 2000. Aggregation of huntingtin in yeast varies with the length of the polyglutamine expansion and the expression of chaperone proteins. Proc. Natl. Acad. Sci. USA 97:1589-94
83. Muchowski PJ, Schaffar G, Sittler A, Wanker EE, Hayer-Hartl MK, Hartl U. 2000. Hsp70 and Hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. Proc. Natl. Acad. Sci. USA 97:7841-46
84. Chan HYE, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM. 2000. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum. Mol. Genet. 9:2811-20
85. Kazemi-Esfarjani P, Benzer S. 2000. Genetic suppression of polyglutamine toxicity in Drosophila. Science 287:1837-40
86. Hansson O, Nylandsted J, Castilho RF, Leist M, Jaattela M, Brundin P. 2003. Overexpression of heat shock protein 70 in R6/2 Huntingtons diseasemice has onlymodest effects on disease progression. Brain Res. 970:47-57
87. Wacker JL, Huang SY, Steela AD, Aron R, Lotz GP, et al. 2009. Loss ofHsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntingtons disease. J. Neurosci. 29:9104-14
88. Tsai YC, Fishman PS, Thakor NV, Oyler GA. 2003. Parkin facilitates the elimination of expanded polyglutamine proteins and leads to preservation of proteasome function. J. Biol. Chem. 278:22044-55
89. Jankovic J. 2007. Parkinsons disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatry 79:368-76
90. Obeso JA, Rodriguez-Oroz MC, Guetz CG, Marin C, Kordower JH, et al. 2010. Missing pieces in the Parkinsons disease puzzle. Nat. Med. 16:653-61
91. Farrer MJ. 2006. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 7:306-18
92. Lee HJ, Lee SJ. 2002. Characterization of cytoplasmicα-Synuclein aggregates: Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277:48976-83
93. Lansbury PT, Lashuel HA. 2006. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443:774-79
94. Bartels T, Chui JG, Selkoe DJ. 2011. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477:107-10
95. Lee VM, Trojanowski JQ. 2006. Mechanisms of Parkinsons disease linked to pathological α-Synuclein: new targets for drug discovery. Neuron 52:33-38
96. Gupta A, Dawson VL, Dawson TM. 2008. What causes cell death in Parkinsons disease? Ann. Neurol. 64:S3-15
97. Uryu K, Richter-Landsberg C, Welch W, Sun E, Goldbaum O, et al. 2006. Convergence of heat shock protein 90 with ubiquitin in filamentous α-Synuclein inclusions of α-Synucleinopathies. Am. J. Pathol. 168:947-61
98. Liang J, Clark-Dixon C, Wang S, Flower TR, Williams-Hart T, et al. 2008. Novel suppressors of α-Synuclein toxicity identified using yeast. Hum. Mol. Genet. 17:3784-95
99. Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN. 2005. Heat shock prevents alphasynuclein- induced apoptosis in a yeast model of Parkinsons disease. J. Mol. Biol. 351:1081-100
100. Auluck PK, Meulener MC, Bonini NM. 2005. Mechanisms of suppression of α-Synuclein neurotoxicity by geldanamycin in Drosophila. J. Biol. Chem. 280:2873-78
101. Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, et al. 2010. Brain-permeable, small-molecule inhibitors of Hsp90 prevent α-Synuclein-induced toxicity. J. Pharmacol. Exp. Ther. 332:849-57
102. Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H. 2003. Part II: α-Synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45:14-44
103. Auluck PK, Chan E, Trojanowski JQ, Lee VM, Bonini NM. 2002. Chaperone suppression ofα-Synuclein toxicity in a Drosophila model for Parkinsons disease. Science 295:865-68
104. McLean PJ, Kawamata H, Shariff S, Hewett J, Sharma N, et al. 2002. Torsin A and heat shock proteins act as molecular chaperones: suppression of α-Synuclein aggregation. J. Neurochem. 83:846-54
105. Zhou Y, Gu G, Goodlett DR, Zhang T, Pan C, et al. 2004. Analysis of α-Synuclein-associated proteins by quantitative proteomics. J. Biol. Chem. 279:39155-64
106. Yu F, Xu HT, Zhuo M, Sun LY, Dong AW, Liu XY. 2005. Impairment of redox state and dopamine level induced by α-Synuclein aggregation and the preventive effect of hsp70. Biochem. Biophys. Res. Commun. 331:278-84
107. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, Koker M, et al. 2008. Formation of toxic oligomeric α-Synuclein species in living cells. PLOS ONE 3:e1867
108. Fan GH, Zhou HY, Yang H, Chen SD. 2006. Heat shock proteins reduce α-Synuclein aggregation induced by MPP+ in SK-N-SH cells. FEBS Lett. 580:3091-98
109. Shin Y, Klucken J, Patterson C, Hyman BT, McLean PJ. 2005. The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates α-Synuclein degradation decisions between proteasomal and lysosomal pathways. J. Biol. Chem. 280:23727-34
110. Kalia LV, Kalia SK, Chau H, Lozano AM, Hymen BJ, McLean PJ. 2011. Ubiquitinylation ofα-Synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by Bcl-2-associated athanogene 5 (BAG5). PLOS ONE 6:e14695
111. Cummings JL. 2004. Alzheimers disease. N. Eng. J. Med. 351:56-67
112. Burns A, Iliffe S. 2009. Alzheimers disease. Br. Med. J. 338:467-71
113. Citron M. 2010. Alzheimers disease: strategies for disease modification. Nat. Rev. Drug Disc. 9:387-98
114. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimers disease: progress and problems on the road to therapeutics. Science 297:353-56
115. Mesulam MM. 1999. Neuroplasticity failure in Alzheimers disease: bridging the gap between plaques and tangles. Neuron 24:521-29
116. Morris M, Maeda S, Vossel K, Mucke L. 2011. The many faces of tau. Neuron 70:410-26
117. Lee VM, Goedert M, Trojanowski JQ. 2001. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:1121-59
118. Takei Y, Teng J, Harada A, Hirokawa N. 2000. Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes. J. Cell Biol. 150:989-1000
119. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B, et al. 1998. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimers disease. J. Cell Biol. 143:777-94
120. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM. 2002. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156:1051-63
121. Dixit R, Ross JL, Goldman YE, Holzbaur ELF. 2008. Differential regulation of dynein and kinesin motor proteins by tau. Science 319:1086-89
122. Feuillette S, Miguel L, Frebourg T, Campion D, Lecourtois M. 2010. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein. J. Neurochem. 113:895-903
123. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. 2007. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimers disease mouse model. Science 316:750-54
124. Dou F, Natzer WJ, Tanemura K, Li F, Hartl FU, et al. 2003. Chaperones increase association of tau protein with microtubules. Proc. Natl. Acad. Sci. USA 100:721-26
125. Luo W, Dou F, Rodina A, Chip S, Kim J, et al. 2007. Roles of heat-shock protein 90 in maintaining and facilitating the neurodegenerative phenotype in tauopathies. Proc. Natl. Acad. Sci. USA 104:9511-16
126. Tortosa E, Santa-Maria I, Moreno F, Lim F, Perez M, Avila J. 2009. Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein. J. Alzheimers Dis. 17:319-25
127. Dicky CA, Dunmore J, Lu B, Wang JW, Lee WC, et al. 2006. HSP induction mediates selective clearance of tau phosphorylated at proline-directed Ser/Thr sites but not KXGS (MARK) sites. FASEB J. 20:753-55
128. Dicky CA, Kamal A, Lundgren K, Klosak N, Bailey RM, et al. 2007. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. J. Clin. Invest. 117:648-58
129. Petrucelli L, Dickson D, Kehoe K, Taylor J, Snyder H, et al. 2004. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Hum. Mol. Genet. 13:703-14
130. Shimura H, Schwartz D, Gygi SP, Kosik KS. 2004. CHIP-Hsp70 complex ubiquitinates phosphorylated tau and enhances cell survival. J. Biol. Chem. 279:4869-76
131. Hatakeyama S, Matsumoto M, Kamura T, Murayama M, Chui DH, et al. 2004. U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates poly-ubiquitination preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy. J. Neurochem. 91:299-307
132. Dickey CA, Yue M, Lin WL, Dickson DW, Dunmore JH, et al. 2006. Deletion of the ubiquitin ligase CHIP leads to the accumulation, but not the aggregation, of both endogenous phospho- and caspase-3- cleaved tau species. J. Neurosci. 26:6985-96
133. Sahara N, Murayama M, Mizoroki T, Urushitani M, Imai Y, et al. 2005. In vivo evidence of CHIP up-regulation attenuating tau aggregation. J. Neurochem. 94:1254-63
134. Abisambra J, Jinwal UK, Miyata Y, Rogers J, Blair L, et al. 2013. Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau. Biol. Psychiatry 74:367-74